Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Enzymotec Granted Israeli patent for, CardiaBeat®
January 21, 2009
1 Min Read
Enzymotec received the Israel patent office approval for CardiaBeat® composition and production process. The patent entitled "Fractionation of phytosterol esters in oil" (IL 162764) was granted on Aug. 11, 2008, following approvals from New Zealand and China patent offices.
CardiaBeat is a lipid-regulating agent, composed of plant sterol esters of omega-3 fatty acids in an omega-3 glyceride matrix. CardiaBeat efficacy in reducing cardiovascular disease risk factors was evaluated in several clinical trials. The ingredient has additional pending patents around the world and it has already gained a NDI status in the U.S. and a novel food approval in the European Union.
You May Also Like
